Marinus Pharmaceuticals (MRNS) Now Covered by Analysts at Mizuho
Equities researchers at Mizuho initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report issued on Monday, The Fly reports. The brokerage set a “buy” rating and a $13.00 price target on the biopharmaceutical company’s stock. Mizuho’s target price suggests a potential upside of 217.85% from the stock’s previous close.
The analysts wrote, “We see the recent positive data from Sage in PPD and major depressive disorder (MDD) as positive read-throughs for Marinus. With important potential catalysts in 2H18 and a favorable risk-reward ratio, we initiate with a Buy and $13 PT. KeyPoints Strong Potential for Ganaxolone in CNS Indications. Marinus Pharmaceuticals’ lead molecule is ganaxolone, a proprietary formulation of Allopregnanolone, similar to Sage Therapeutics’ Brenaxolone. Multiple clinical trials have shown the therapeutic benefits of both companies’ molecules in a number of CNS indications including Postpartum depression (PPD), Major depressive disorder (MDD) and CDKL5 Disorder. Sage Therapeutics’ PPD and MDD Results are Positives for Marinus. Late last year, Sage reported positive results from a phase 3 trial of Brenaxolone in PPD as well as from a phase 2 trial in MDD.””
Other analysts have also recently issued reports about the company. BidaskClub raised Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, December 30th. Laidlaw started coverage on Marinus Pharmaceuticals in a research note on Thursday, December 14th. They set a “buy” rating and a $18.00 target price for the company. HC Wainwright started coverage on Marinus Pharmaceuticals in a research note on Thursday, February 15th. They set a “buy” rating and a $33.00 target price for the company. Finally, ValuEngine cut Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $18.75.
Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its earnings results on Tuesday, March 6th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.07).
In other news, major shareholder Bain Capital Life Sciences Inv sold 1,272,547 shares of the firm’s stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $7.88, for a total transaction of $10,027,670.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Christopher Michael Cashman sold 9,566 shares of the firm’s stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $6.28, for a total transaction of $60,074.48. Following the transaction, the chief executive officer now directly owns 247,903 shares of the company’s stock, valued at $1,556,830.84. The disclosure for this sale can be found here. Insiders have sold a total of 1,285,113 shares of company stock valued at $10,111,475 over the last ninety days. Company insiders own 4.60% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. 683 Capital Management LLC bought a new position in shares of Marinus Pharmaceuticals during the 4th quarter worth approximately $4,488,000. Millennium Management LLC grew its stake in shares of Marinus Pharmaceuticals by 5.5% in the fourth quarter. Millennium Management LLC now owns 915,620 shares of the biopharmaceutical company’s stock valued at $7,471,000 after buying an additional 47,693 shares in the last quarter. Nexthera Capital LP grew its stake in shares of Marinus Pharmaceuticals by 54.2% in the fourth quarter. Nexthera Capital LP now owns 925,327 shares of the biopharmaceutical company’s stock valued at $7,551,000 after buying an additional 325,327 shares in the last quarter. Goldman Sachs Group Inc. bought a new position in shares of Marinus Pharmaceuticals in the fourth quarter valued at $305,000. Finally, Deutsche Bank AG grew its stake in shares of Marinus Pharmaceuticals by 208,007.5% in the fourth quarter. Deutsche Bank AG now owns 416,215 shares of the biopharmaceutical company’s stock valued at $3,396,000 after buying an additional 416,015 shares in the last quarter. 63.49% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Marinus Pharmaceuticals (MRNS) Now Covered by Analysts at Mizuho” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.watchlistnews.com/mizuho-initiates-coverage-on-marinus-pharmaceuticals-mrns/1946872.html.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.